Enliven Therapeutics (NASDAQ:ELVN) Trading Up 4.7%

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) shares were up 4.7% during mid-day trading on Thursday . The company traded as high as $18.12 and last traded at $18.12. Approximately 39,716 shares were traded during mid-day trading, a decline of 81% from the average daily volume of 214,132 shares. The stock had previously closed at $17.30.

Analysts Set New Price Targets

Separately, Mizuho started coverage on shares of Enliven Therapeutics in a research report on Tuesday, April 9th. They issued a "buy" rating and a $34.00 target price for the company.

Enliven Therapeutics Trading Up 2.1 %

The stock's 50-day moving average is $16.98 and its 200-day moving average is $14.31. The stock has a market cap of $827.13 million, a P/E ratio of -8.08 and a beta of 1.06.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last issued its quarterly earnings results on Thursday, March 14th. The company reported ($0.47) earnings per share for the quarter, beating analysts' consensus estimates of ($0.56) by $0.09. On average, equities analysts forecast that Enliven Therapeutics, Inc. will post -2.16 EPS for the current year.

Insider Buying and Selling at Enliven Therapeutics

In other Enliven Therapeutics news, major shareholder 5Am Partners Vi, Llc sold 500,000 shares of the company's stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $15.00, for a total value of $7,500,000.00. Following the completion of the sale, the insider now directly owns 771,983 shares of the company's stock, valued at approximately $11,579,745. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Enliven Therapeutics news, insider Joseph P. Lyssikatos sold 12,000 shares of the company's stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $15.85, for a total transaction of $190,200.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder 5Am Partners Vi, Llc sold 500,000 shares of the company's stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $15.00, for a total transaction of $7,500,000.00. Following the sale, the insider now directly owns 771,983 shares of the company's stock, valued at $11,579,745. The disclosure for this sale can be found here. In the last three months, insiders sold 763,661 shares of company stock valued at $13,213,762. 45.80% of the stock is owned by insiders.

Institutional Trading of Enliven Therapeutics

A number of hedge funds have recently made changes to their positions in ELVN. AJOVista LLC purchased a new stake in shares of Enliven Therapeutics in the fourth quarter worth approximately $28,000. Tower Research Capital LLC TRC purchased a new stake in shares of Enliven Therapeutics in the first quarter worth approximately $36,000. Ameritas Investment Partners Inc. purchased a new stake in shares of Enliven Therapeutics in the second quarter worth approximately $39,000. Royal Bank of Canada increased its holdings in Enliven Therapeutics by 532.7% in the second quarter. Royal Bank of Canada now owns 3,075 shares of the company's stock worth $63,000 after buying an additional 2,589 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. bought a new position in Enliven Therapeutics during the fourth quarter valued at approximately $66,000. 95.08% of the stock is owned by hedge funds and other institutional investors.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.